TriSalus Life Sciences (TLSI) Total Debt (2022 - 2026)

TriSalus Life Sciences has reported Total Debt for 5 years, with the latest figure at $33.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 4.35% year-over-year to $33.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.1 million (up 4.35% YoY), and the FY2025 full-year result was $33.0 million, up 49.64% from the prior year.
• Total Debt for Q1 2026 stood at $33.1 million, roughly flat from $33.0 million in the prior quarter.
• The five-year high for Total Debt was $33.1 million in Q1 2026, with the low at $2.5 million in Q4 2022.
• Historically, Total Debt has averaged $22.3 million across 5 years, with a median of $22.1 million in 2024.
• Annual changes were most pronounced in 2024 — Total Debt jumped 111.86% — and 2026, when it increased 4.35%.
• TriSalus Life Sciences' Total Debt stood at $2.5 million in 2022, then surged by 309.75% to $10.0 million in 2023, then surged by 119.81% to $22.1 million in 2024, then soared by 49.64% to $33.0 million in 2025, then advanced by 0.1% to $33.1 million in 2026.
• The last three Total Debt figures came in at $33.1 million (Q1 2026), $33.0 million (Q4 2025), and $32.8 million (Q3 2025), per Business Quant data.